Abstract

This study aimed to determine the anti-proliferative and anti-migratory effects of 7-methoxy-1-tetralone (MT) in hepatocellular carcinoma (HCC) cells. MTT assay assessed HCC cell viability; cell apoptosis of HCC cells was determined by flow cytometry; wound healing assay evaluated HCC cell migratory ability; protein expression levels were assessed using western blot assay; the in vivo antitumor effects of MT were tested in BALB/c nude mice and the pathological changes within the tumor tissues were evaluated by immunohistochemistry. MT treatment significantly suppressed the cell proliferative and migratory potentials of HepG2 cells, and induced HepG2 cell apoptosis. The western blot assay showed that MT treatment caused a suppression on c-Met, phosphorylated AKT (p-AKT), NF-κB, matrix metallopeptidase 2 (MMP2)/MMP9 protein levels in HepG2 cells. Further in vivo animal studies deciphered that MT treatment suppressed tumor growth of HepG2 cells in the nude mice, but had no effect on the body weight and the organ index of liver and spleen. Further immunohistochemistry analysis of the dissected tumor tissues showed that MT treatment significantly suppressed the protein expression levels of NF-κB, MMP9, MMP2, and p-AKT. In summary, the present study demonstrated the anti-tumor effects of MT on the HCC, and MT suppressed HCC progression possibly via regulating proliferation- and migration-related mediators including c-Met, p-AKT, NF-κB, MMP2, and MMP9 in HepG2 cells.

Highlights

  • Hepatocellular carcinoma (HCC) represents one of the most severe human malignancies with a high mortality [1]

  • We demonstrated the antitumor effects of MT against hepatocellular carcinoma (HCC) progression and deciphered the underlying molecular mechanisms

  • Our results illustrated that MT treatment concentration-dependently repressed HCC cell viability

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) represents one of the most severe human malignancies with a high mortality [1]. High risk factors such as hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, alcohol abuse, hemochromatosis psychosis, and so on, may lead to a chronic liver disease, with progression to cirrhosis, eventually leading to the occurrence of HCC [2,3,4]. Sorafenib is the only FDA-approved medication for the management of advanced HCC [9, 10]. There is still a large unmet medical need to develop new therapeutic strategies to treat HCC

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call